Edition:
United States

Biotechnology & Medical Research

Page 2

Insys Therapeutics replaces 90 pct of original sales force

Friday, 6 Oct 2017 09:00am EDT

Oct 6 (Reuters) - Insys Therapeutics Inc : :Insys Therapeutics addresses New Jersey complaint.Insys Therapeutics inc - ‍company is under new management and has replaced 90 percent of original sales force and commercial organization​.Insys Therapeutics says it continues to work with relevant authorities to resolve issues related to inappropriate actions taken by some of co's former employees​.‍Accordingly, co has taken "a series of major actions to prevent mistakes of past from happening in future​".

CytRx Corp provides business update and highlights future plans

Monday, 2 Oct 2017 09:00am EDT

Oct 2 (Reuters) - CytRx Corp :CytRx Corp provides business update and highlights future plans.CytRx Corp - hopes to nominate next Linker Activated Drug Release discovery platform candidate for clinical development by end of 2017.CytRx Corp - CytRx ended Q2 of 2017 with $55 million in cash.CytRx Corp - restructured and paid down $10 million of its existing debt during Q3.

VIKING THERAPEUTICS ANNOUNCES PURCHASE AGREEMENTS FOR UP TO $16.25 MILLION WITH LINCOLN PARK CAPITAL

Friday, 29 Sep 2017 07:05am EDT

Sept 29 (Reuters) - Viking Therapeutics Inc ::VIKING THERAPEUTICS ANNOUNCES PURCHASE AGREEMENTS FOR UP TO $16.25 MILLION WITH LINCOLN PARK CAPITAL.VIKING THERAPEUTICS INC - ‍ANNOUNCED IT HAS ENTERED INTO A $15.0 MILLION COMMON STOCK PURCHASE AGREEMENT WITH LINCOLN PARK CAPITAL FUND LLC​.VIKING THERAPEUTICS INC - CONTINUE TO ANTICIPATE TOP LINE RESULTS FROM PHASE 2 TRIAL OF VK5211 IN HIP FRACTURE IN Q4 OF 2017.VIKING THERAPEUTICS - CO WILL HAVE RIGHT AND SOLE DISCRETION TO SELL TO LPC UP TO $15 MILLION IN SHARES OF COMMON STOCK OVER 30-MONTH PERIOD CONTINGENT.VIKING THERAPEUTICS - ‍UNDER SEPARATE PURCHASE AGREEMENT, LINCOLN PARK CAPITAL FUND AGREED TO BUY $1.25 MILLION OF CO'S STOCK AT $1.78 PER SHARE​.VIKING THERAPEUTICS - ‍UNDER TERMS OF COMMON STOCK PURCHASE AGREEMENT, CO TO CONTROL TIMING, AMOUNT OF ANY FUTURE SALE OF SHARES OF COMMON STOCK TO LPC​.

Bellerophon announces $23 million private placement

Wednesday, 27 Sep 2017 08:30am EDT

Sept 27 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon announces $23 million private placement.Bellerophon Therapeutics Inc - ‍financing was led by Puissance Capital Management and Venrock Healthcare Capital Partners​.Bellerophon Therapeutics Inc - will sell about 19.4 million shares of stock, warrants to purchase about 19.4 million shares of stock for about $23.4 million.

GTx announces $48.5 million private placement

Tuesday, 26 Sep 2017 07:30am EDT

Sept 26 (Reuters) - Gtx Inc :GTx announces $48.5 million private placement.GTx - ‍entered into agreement for sale of its common stock & warrants to purchase common stock in private placement with gross proceeds of $48.5 million.GTx -under terms of agreement, at close of placement, co will issue, sell 5.5 million shares to purchase up to 3.3 million additional shares of common stock.GTx Inc - co ‍to purchase up to 3.3 million additional shares of common stock at a per unit purchase price of $8.845​.

EPS Holdings unit to fully acquire Sapporo-based firm EXAM

Tuesday, 26 Sep 2017 03:38am EDT

Sept 26 (Reuters) - EPS Holdings Inc <4282.T>:Says co's unit EP-SOGO Co., Ltd plans to fully acquire a Sapporo-based firm EXAM Co.,Ltd on Oct. 2.Says EXAM is mainly engaged in site management organization (SMO) business .Says acquisition price is undisclosed .

Aldeyra Therapeutics announces proposed public offering of common stock

Monday, 18 Sep 2017 04:01pm EDT

Sept 18 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra Therapeutics Inc announces proposed public offering of common stock.Aldeyra Therapeutics - To offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering​.Aldeyra Therapeutics Inc says ‍net proceeds to be used for continued development of Aldeyra's lead compound ADX-102 and other product candidates​.

Guangzhou Boji Medical's shares to resume trade after halting restructuring plan

Monday, 18 Sep 2017 05:39am EDT

Sept 18 (Reuters) - Guangzhou Boji Medical & Biotechnological Co Ltd <300404.SZ>:Says its shares to resume trade on Sept 19 after halting asset restructuring plan.

Achieve announces share purchase agreement with Lincoln Park Capital Fund

Thursday, 14 Sep 2017 04:06pm EDT

Sept 14 (Reuters) - Achieve Life Sciences Inc :Achieve announces share purchase agreement with Lincoln Park Capital Fund LLC.Achieve Life Sciences - ‍Entered share purchase agreement with Lincoln Park Capital Fund pursuant to which achieve may sell up to $11.0 million of shares.Achieve Life Sciences - Intends to use net proceeds it receives from offering to advance clinical development of Cytisine, among others​.

Epizyme announces proposed public offering of common stock

Wednesday, 13 Sep 2017 04:01pm EDT

Sept 13 (Reuters) - Epizyme Inc :Epizyme announces proposed public offering of common stock.Epizyme Inc says ‍intends to offer and sell $120 million of shares of its common stock in an underwritten public offering​.Epizyme-Will use ‍net proceeds from this offering,existing cash, cash equivalents,marketable securities,to fund development costs of tazemetostat outside Japan​.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary